Randomized Trial of Intravitreal Bevacizumab Alone or Combined with Triamcinolone versus Macular Photocoagulation in Diabetic Macular Edema

Ophthalmology

Volumn 116, Issue 6, 2009, Pages 1142-1150

  Soheilian, Masoud ^a,b   Ramezani, Alireza ^a,b   Obudi, Arash ^a,b   Bijanzadeh, Bijan ^a,b   Salehipour, Masoud ^a,b   Yaseri, Mehdi ^c   Ahmadieh, Hamid ^a,b   Dehghan, Mohammad H ^a,b   Azarmina, Mohsen ^a,b   Moradian, Siamak ^a,b   Peyman, Gholam A ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Negah Eye Hospital   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE;

ADULT; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; CATARACT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; INTRAOCULAR HYPERTENSION; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; THROMBOEMBOLISM; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 67349168190     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.01.011     Document Type: Article

References (45)

1. Klein R., Klein B.E., and Moss S.E. Visual impairment in diabetes. Ophthalmology 91 (1984) 1-9
2. Hardy R.A., and Crawford J.B. Retina. In: Vaughn D., Asbury T., and Riordan-Eva P. (Eds). General Ophthalmology. 15th ed. (1999), Appleton & Lange, Stamford, CT 178-199
3. Tranos P.G., Wickremasinghe S.S., Stangos N.T., et al. Macular edema. Surv Ophthalmol 49 (2004) 470-490
4. Gottfredsdottir M.S., Stefansson E., Jonasson F., and Gislason I. Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol 115 (1993) 64-67
5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985) 1796-1806
6. Lee C.M., and Olk R.J. Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology 98 (1991) 1594-1602
7. Sutter F.K., Simpson J.M., and Gillies M.C. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111 (2004) 2044-2049
8. Massin P., Audren F., Haouchine B., et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111 (2004) 218-225
9. Gillies M.C., Sutter F.K., Simpson J.M., et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113 (2006) 1533-1538
10. Jonas J.B., Kamppeter B.A., Harder B., et al. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 22 (2006) 200-207
11. Audren F., Erginay A., Haouchine B., et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 84 (2006) 624-630
12. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
13. Chun D.W., Heier J.S., Topping T.M., et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113 (2006) 1706-1712
14. Haritoglou C., Kook D., Neubauer A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26 (2006) 999-1005
15. Starita C., Patel M., Katz B., and Adamis A.P. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy. Dev Ophthalmol 39 (2007) 122-148
16. Sears J.E., and Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Muller cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sci 46 (2005) 4336-4341
17. Gardner T.W., Antonetti D.A., Barber A.J., et al., Penn State Retina Research Group. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 47 suppl (2002) S253-S262
18. Antcliff R.J., and Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14 (1999) 223-232
19. Funatsu H., Yamashita H., Ikeda T., et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110 (2003) 1690-1696
20. Funatsu H., Yamashita H., Sakata K., et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 112 (2005) 806-816
21. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695-1705
22. Soheilian M., Ramezani A., Bijanzadeh B., et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 27 (2007) 1187-1195
23. Pocock S.J. Group sequential methods in the design and analysis of clinical trials. Biometrika 64 (1997) 191-199
24. Bhisitkul R.B. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 90 (2006) 1542-1547
25. Gillies M.C. What we don't know about Avastin might hurt us. Arch Ophthalmol 124 (2006) 1478-1479
26. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114 (2007) 1860-1867
27. Schmid K.E., Neumaier-Ammerer B., Stolba U., and Binder S. Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c). Graefes Arch Clin Exp Ophthalmol 244 (2006) 1446-1452
28. Arevalo J.F., Fromow-Guerra J., Quiroz-Mercado H., et al., Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the at 6-month follow-up. Ophthalmology 114 (2007) 743-750
29. Jin K., Zhu Y., Sun Y., et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A 99 (2002) 11946-11950
30. Oosthuyse B., Moons L., Storkebaum E., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28 (2001) 131-138
31. Ahmadieh H., Ramezani A., Shoeibi N., et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 246 (2008) 483-489
32. Shimura M., Nakazawa T., Yasuda K., et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145 (2008) 854-861
33. Martidis A., Duker J.S., Greenberg P.B., et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109 (2002) 920-927
34. Beer P.M., Bakri S.J., Singh R.J., et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110 (2003) 681-686
35. Nelson M.L., Tennant M.T., Sivalingam A., et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 23 (2003) 686-691
36. Audren F., Lecleire-Collet A., Erginay A., et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 142 (2006) 794-799
37. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema. Version 4.0 (2005) 1-13. http://www.t1diabetes.nih.gov/investigator/resources/Protocol_B.pdf Accessed December 21, 2008
38. Laursen M.L., Moeller F., Sander B., and Sjoelie A.K. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 88 (2004) 1173-1179
39. Thompson M.J., and Ip M.S. Diabetic macular edema: a review of past, present, and future therapies. Int Ophthalmol Clin 44 (2004) 51-67
40. Christoforidis J.B., and D'Amico D.J. Surgical and other treatments of diabetic macular edema: an update. Int Ophthalmol Clin 44 (2004) 139-160
41. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115 (2008) 1447-1459
42. Schachat A.P. A new look at an old treatment for diabetic macular edema. Ophthalmology 115 (2008) 1445-1446
43. Estabrook E.J., Madhusudhana K.C., Hannan S.R., and Newsom R.S. Can optical coherence tomography predict the outcome of laser photocoagulation for diabetic macular edema?. Ophthalmic Surg Lasers Imaging 38 (2007) 478-483
44. Rosenfeld P.J., Fung A.E., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36 (2005) 336-339
45. Mason III J.O., Nixon P.A., and White M.F. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142 (2006) 685-688